[go: up one dir, main page]

WO2019123294A3 - Nouvelles utilisations de dérivés pyrazolo pipéridine - Google Patents

Nouvelles utilisations de dérivés pyrazolo pipéridine Download PDF

Info

Publication number
WO2019123294A3
WO2019123294A3 PCT/IB2018/060309 IB2018060309W WO2019123294A3 WO 2019123294 A3 WO2019123294 A3 WO 2019123294A3 IB 2018060309 W IB2018060309 W IB 2018060309W WO 2019123294 A3 WO2019123294 A3 WO 2019123294A3
Authority
WO
WIPO (PCT)
Prior art keywords
pyrazolo
treatment
lupus erythematosus
systemic lupus
pyrimidine derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2018/060309
Other languages
English (en)
Other versions
WO2019123294A2 (fr
Inventor
Jonathan DEANE
Tobias Junt
Pius Loetscher
Barbara Nuesslein-Hildesheim
Ben Wen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Priority to CN201880078211.3A priority Critical patent/CN111432818A/zh
Priority to JP2020533229A priority patent/JP2021507889A/ja
Publication of WO2019123294A2 publication Critical patent/WO2019123294A2/fr
Publication of WO2019123294A3 publication Critical patent/WO2019123294A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La présente invention concerne l'utilisation de certains dérivés pyrazolo pipéridine dans le traitement de maladies et d'états associés à l'interaction du récepteur de type toll. Plus particulièrement, ledit traitement est un traitement de lupus neuropsychiatrique (NPSLE).
PCT/IB2018/060309 2017-12-22 2018-12-19 Nouvelles utilisations de dérivés pyrazolo pipéridine Ceased WO2019123294A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN201880078211.3A CN111432818A (zh) 2017-12-22 2018-12-19 用于治疗神经精神性系统性红斑狼疮的吡唑并哌啶衍生物和吡唑并嘧啶衍生物
JP2020533229A JP2021507889A (ja) 2017-12-22 2018-12-19 ピラゾロピペリジン誘導体の新規な使用

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP17210059 2017-12-22
EP17210059.6 2017-12-22
US201862769635P 2018-11-20 2018-11-20
US62/769,635 2018-11-20

Publications (2)

Publication Number Publication Date
WO2019123294A2 WO2019123294A2 (fr) 2019-06-27
WO2019123294A3 true WO2019123294A3 (fr) 2019-08-01

Family

ID=65201642

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2018/060309 Ceased WO2019123294A2 (fr) 2017-12-22 2018-12-19 Nouvelles utilisations de dérivés pyrazolo pipéridine

Country Status (3)

Country Link
JP (1) JP2021507889A (fr)
CN (1) CN111432818A (fr)
WO (1) WO2019123294A2 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111699187A (zh) 2018-02-12 2020-09-22 豪夫迈·罗氏有限公司 用于治疗和预防病毒感染的新的砜化合物和衍生物
WO2019233941A1 (fr) 2018-06-05 2019-12-12 F. Hoffmann-La Roche Ag Composés tétrahydro-1h-pyrazino[2,1-ajisoindolylquinoline pour le traitement d'une maladie auto-immune
US11713327B2 (en) 2018-06-12 2023-08-01 Hoffmann-La Roche Inc. Heteroaryl heterocyclyl compounds for the treatment of autoimmune disease
JP7366994B2 (ja) 2018-07-23 2023-10-23 エフ． ホフマン－ラ ロシュ アーゲー 自己免疫疾患治療用の新規ピペラジン化合物
US11639352B2 (en) 2018-09-04 2023-05-02 Hoffman-La Roche Inc. Benzothiazole compounds for the treatment of autoimmune diseases
WO2020048595A1 (fr) 2018-09-06 2020-03-12 F. Hoffmann-La Roche Ag Nouveaux composés amidine cyclique pour le traitement d'une maladie auto-immune
WO2020048596A1 (fr) 2018-09-06 2020-03-12 F. Hoffmann-La Roche Ag Nouveaux composés de pyrazolopyridine pour le traitement d'une maladie auto-immune
WO2021084022A1 (fr) 2019-10-31 2021-05-06 F. Hoffmann-La Roche Ag Composés d'hydropyrazino[1,2-d][1,4]diazépine pour le traitement d'une maladie auto-immune
CN114728976B (zh) 2019-11-19 2024-08-16 豪夫迈·罗氏有限公司 用于治疗自身免疫性疾病的氢-1H-吡咯并[1,2-a]吡嗪化合物
WO2021099406A1 (fr) 2019-11-20 2021-05-27 F. Hoffmann-La Roche Ag Composés de spiro(isobenzofurane azétidine) pour le traitement d'une maladie auto-immune
AU2022257039A1 (en) 2021-04-16 2023-10-05 Gilead Sciences, Inc. Thienopyrrole compounds
WO2023039464A1 (fr) 2021-09-10 2023-03-16 Gilead Sciences, Inc. Composés de thiénopyrrole
MX2024008626A (es) * 2022-01-11 2024-07-23 Novartis Ag Antagonista de tlr7/8 para el tratamiento del sindrome de sjogren o la enfermedad mixta del tejido conectivo.

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015057655A1 (fr) * 2013-10-14 2015-04-23 Eisai R&D Management Co., Ltd. Composés de quinoléine substitués de manière sélective
WO2018047081A1 (fr) * 2016-09-09 2018-03-15 Novartis Ag Composés et compositions en tant qu'inhibiteurs de récepteurs de type toll endosomal

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3407B1 (ar) 2012-05-31 2019-10-20 Eisai R&D Man Co Ltd مركبات رباعي هيدرو بيرازولو بيريميدين
KR101865120B1 (ko) 2016-06-29 2018-06-08 숭실대학교 산학협력단 테스트 노드 기반의 무선 측위 방법 및 그 장치

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015057655A1 (fr) * 2013-10-14 2015-04-23 Eisai R&D Management Co., Ltd. Composés de quinoléine substitués de manière sélective
WO2018047081A1 (fr) * 2016-09-09 2018-03-15 Novartis Ag Composés et compositions en tant qu'inhibiteurs de récepteurs de type toll endosomal

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ALLISON R. BIALAS ET AL: "Microglia-dependent synapse loss in type I interferon-mediated lupus", NATURE, 14 June 2017 (2017-06-14), GB, XP055476303, ISSN: 0028-0836, DOI: 10.1038/nature22821 *
CÉSAR MAGRO-CHECA ET AL: "Management of Neuropsychiatric Systemic Lupus Erythematosus: Current Approaches and Future Perspectives", DRUGS, vol. 76, no. 4, 26 January 2016 (2016-01-26), NZ, pages 459 - 483, XP055476422, ISSN: 0012-6667, DOI: 10.1007/s40265-015-0534-3 *
WANG H P ET AL: "Cystamine attenuates the expressions of NOS- and TLR-associated molecules in the brain of NZB/W F1 mice", EUROPEAN JOURNAL OF PHARMACOLOGY, ELSEVIER SCIENCE, NL, vol. 607, no. 1-3, 1 April 2009 (2009-04-01), pages 102 - 106, XP026007773, ISSN: 0014-2999, [retrieved on 20090304], DOI: 10.1016/J.EJPHAR.2009.02.039 *

Also Published As

Publication number Publication date
CN111432818A (zh) 2020-07-17
JP2021507889A (ja) 2021-02-25
WO2019123294A2 (fr) 2019-06-27

Similar Documents

Publication Publication Date Title
WO2019123294A3 (fr) Nouvelles utilisations de dérivés pyrazolo pipéridine
MX2020012562A (es) Agonista del receptor de glucocorticoides e inmunoconjugados del mismo.
ZA202311311B (en) Anti-bcma heavy chain-only antibodies
PH12017501780A1 (en) Maytansinoid derivatives, conjugates thereof, and methods of use
CL2018002012A1 (es) Derivados de maitansinoide, conjugados de los mismos y métodos de uso.
PH12018501153A1 (en) Novel anti-claudin antibodies and methods of use
MX2024014319A (es) Anticuerpos anti-bcma unicamente de cadena pesada
MX2015011132A (es) Moduladores policiclicos del receptor de estrogenos y sus usos.
SG10201808053XA (en) Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
MX2017003478A (es) Anticuerpos anti-fgfr2/3 y metodos para su uso.
MX2015016171A (es) Moduladores del receptor de estrogeno de azetidina y usos de los mismos.
EP3711780A3 (fr) Conjugués anticorps-médicament anti-ptk7
MX363118B (es) Derivados de pirazol aminopirimidina como moduladores de cinasa 2 de repeticion rica en leucina (lrrk2).
HUE053704T2 (hu) 3-szubsztitutált 5-amino-6H-tiazolo[4,5-d]pirimidin-2,7-dion vegyületek vírusfertõzések kezelésére és megelõzésére
NZ733055A (en) Anti-c10orf54 antibodies and uses thereof
MY197534A (en) Anti-tryptase antibodies, compositions thereof, and uses thereof
MY195016A (en) Optionally Fused Heterocyclyl-Substituted Derivatives of Pyrimidine Useful for The Treatment of Inflammatory, Metabolic, Oncologic and Autoimmune Diseases
WO2018067520A3 (fr) Procédés et agents thérapeutiques
EP3773658A4 (fr) Kir3dl3 utile en tant que récepteur hhla2, anticorps anti-hhla2 et leurs utilisations
CL2019001329A1 (es) Composiciones farmacéuticas moduladoras del receptor 7 de 5-hidroxitritpina y métodos de uso.
EP3310358A4 (fr) Compositions et procédés pour le traitement de troubles d'utilisation de substances, d'accoutumance, et de troubles psychiatriques
CL2016000939A1 (es) Compuestos derivados de pirimidina con actividad inhibidora de syk uso en el tratamiento de una condición inmune, enfermedades inflamatorias, trastornos alérgicos, lupus eritomatosos, epoc, bronquitis, rinitis alérgica, asma, entre otras composición farmacéutica que los comprende.
AU2018253600A1 (en) Dosage forms and therapeutic uses of l-4-chlorokynurenine
WO2018094106A3 (fr) Antagonistes allostériques de gprc6a et leur utilisation dans l'atténuation de protéinopathies
CR20220661A (es) NUEVOS DERIVADOS DE [1,2,3]TRIAZOLO[4,5-D]PIRIMIDINA (Divisional 2018-0615)

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18839619

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2020533229

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18839619

Country of ref document: EP

Kind code of ref document: A2